RBC Capital Reiterates Outperform on Nuvation Bio, Maintains $20 Price Target

Benzinga Newsdesk www.benzinga.com Negative 75.5%

Neg 75.5% Neu 0% Pos 0%

RBC Capital analyst Leonid Timashev reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $20 price target.